Gentherm (THRM) 10-Q 27 Apr 23 2023 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2023	Apr. 21, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Trading Symbol	THRM
Entity Registrant Name	GENTHERM INCORPORATED
Entity Central Index Key	0000903129
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		33,127,634
Entity Shell Company	false
Entity File Number	0-21810
Entity Tax Identification Number	95-4318554
Entity Address, Address Line One	21680 Haggerty Road
Entity Address, City or Town	Northville
Entity Address, State or Province	MI
Entity Address, Postal Zip Code	48167
City Area Code	248
Local Phone Number	504-0500
Entity Interactive Data Current	Yes
Entity Incorporation, State or Country Code	MI
Document Quarterly Report	true
Security Exchange Name	NASDAQ
Title of 12(b) Security	Common Stock, no par value
Document Transition Report	false

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 166,630	$ 153,891
Accounts receivable, net	256,715	247,131
Inventory:
Raw materials	137,829	136,217
Work in process	17,091	17,695
Finished goods	63,543	64,336
Inventory, net	218,463	218,248
Other current assets	69,691	64,597
Total current assets	711,499	683,867
Property and equipment, net	242,143	244,480
Goodwill	120,955	119,774
Other intangible assets, net	72,051	73,933
Operating lease right-of-use assets	31,024	29,945
Deferred income tax assets	73,004	69,840
Other non-current assets	18,070	17,461
Total assets	1,268,746	1,239,300
Current Liabilities:
Accounts payable	207,887	182,225
Current lease liabilities	8,093	7,143
Current maturities of long-term debt	1,996	2,443
Other current liabilities	88,896	93,814
Total current liabilities	306,872	285,625
Long-term debt, less current maturities	232,558	232,653
Non-current lease liabilities	19,740	20,538
Pension benefit obligation	3,326	3,638
Other non-current liabilities	25,932	24,573
Total liabilities	588,428	567,027
Common Stock:
No par value; 55,000,000 shares authorized 33,126,702 and 33,202,082 issued and outstanding at March 31, 2023 and December 31, 2022, respectively	112,420	122,658
Paid-in capital	5,379	5,447
Accumulated other comprehensive loss	(36,101)	(46,489)
Accumulated earnings	598,620	590,657
Total shareholders’ equity	680,318	672,273
Total liabilities and shareholders’ equity	$ 1,268,746	$ 1,239,300

Consolidated Condensed Balanc_2

Consolidated Condensed Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common Stock, par value
Common Stock, shares authorized	55,000,000	55,000,000
Common Stock, shares issued	33,126,702	33,202,082
Common Stock, shares outstanding	33,126,702	33,202,082

Consolidated Condensed Statemen

Consolidated Condensed Statements of Income - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Product revenues	$ 363,625	$ 267,657
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember
Cost of sales	$ 282,495	$ 203,544
Gross margin	81,130	64,113
Operating expenses:
Net research and development expenses	25,145	20,434
Selling, general and administrative expenses	37,042	29,308
Restructuring expenses	1,269	181
Total operating expenses	63,456	49,923
Operating income	17,674	14,190
Interest expense, net	(4,144)	(569)
Foreign currency (loss) gain	(2,069)	2,217
Other income	230	204
Earnings before income tax	11,691	16,042
Income tax expense	3,728	4,295
Net income	$ 7,963	$ 11,747
Basic earnings per share	$ 0.24	$ 0.36
Diluted earnings per share	$ 0.24	$ 0.35
Weighted average number of shares – basic	33,181,828	33,034,872
Weighted average number of shares – diluted	33,386,134	33,376,764

Consolidated Condensed Statem_2

Consolidated Condensed Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Statement of Comprehensive Income [Abstract]
Net income	$ 7,963	$ 11,747
Other comprehensive income:
Pension benefit obligations	4	29
Foreign currency translation adjustments	8,255	(9,294)
Unrealized gain on foreign currency derivative securities, net of tax	2,129	464
Unrealized loss on commodity derivative securities, net of tax		(5)
Other comprehensive income (loss), net of tax	10,388	(8,806)
Comprehensive income	$ 18,351	$ 2,941

Consolidated Condensed Statem_3

Consolidated Condensed Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating Activities:
Net income	$ 7,963	$ 11,747
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization	13,583	9,577
Deferred income taxes	(1,786)	(778)
Stock based compensation	2,023	2,279
Loss on disposition of property and equipment	16	107
Provisions for inventory	1,704	747
Other	(44)	256
Changes in assets and liabilities:
Accounts receivable, net	(8,237)	(25,788)
Inventory	(1,137)	(18,863)
Other assets	(6,417)	(10,716)
Accounts payable	24,289	34,097
Other liabilities	(6,848)	(3,349)
Net cash provided by (used in) operating activities	25,109	(684)
Investing Activities:
Purchases of property and equipment	(6,294)	(5,659)
Proceeds from the sale of property and equipment	17	52
Proceeds from deferred purchase price of factored receivables	3,728
Cost of technology investments		(350)
Net cash used in investing activities	(2,549)	(5,957)
Financing Activities:
Repayments of debt	(564)
Proceeds from the exercise of Common Stock options	263	569
Taxes withheld and paid on employees' share-based payment awards	(2,667)	(4,319)
Cash paid for the repurchase of Common Stock	(9,997)
Net cash used in financing activities	(12,965)	(3,750)
Foreign currency effect	3,144	(2,298)
Net increase (decrease) in cash and cash equivalents	12,739	(12,689)
Cash and cash equivalents at beginning of period	153,891	190,606
Cash and cash equivalents at end of period	166,630	177,917
Supplemental disclosure of cash flow information:
Cash paid for taxes	5,536	3,267
Cash paid for interest	3,235	421
Non-Cash Investing Activities:
Period-end balance of accounts payable for property and equipment	2,370	$ 2,437
Deferred purchase price of receivables factored in the period	$ 4,739

Consolidated Condensed Statem_4

Consolidated Condensed Statements of Changes In Shareholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Earnings
Beginning Balance at Dec. 31, 2021	$ 653,806	$ 118,646	$ 5,866	$ (36,922)	$ 566,216
Beginning Balance (in shares) at Dec. 31, 2021		33,008,000
Net income	11,747				11,747
Other comprehensive income (loss)	(8,806)			(8,806)
Stock compensation, net	(960)	$ (814)	(146)
Stock compensation, net, shares		119,000
Ending Balance at Mar. 31, 2022	655,787	$ 117,832	5,720	(45,728)	577,963
Ending Balance (in shares) at Mar. 31, 2022		33,127,000
Beginning Balance at Dec. 31, 2022	$ 672,273	$ 122,658	5,447	(46,489)	590,657
Beginning Balance (in shares) at Dec. 31, 2022	33,202,082	33,202,000
Net income	$ 7,963				7,963
Other comprehensive income (loss)	10,388			10,388
Stock compensation, net	(309)	$ (241)	(68)
Stock compensation, net, shares		94,000
Stock repurchase	(9,997)	$ (9,997)
Stock repurchase (in shares)		(169,000)
Ending Balance at Mar. 31, 2023	$ 680,318	$ 112,420	$ 5,379	$ (36,101)	$ 598,620
Ending Balance (in shares) at Mar. 31, 2023	33,126,702	33,127,000

Overview

Overview	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Overview	Note 1 – Overview Gentherm Incorporated, a Michigan corporation, and its consolidated subsidiaries (“Gentherm”, “we”, “us”, “our” or the “Company”) is the global market leader of innovative thermal management and pneumatic comfort technologies for the automotive and medical industries. Automotive products include variable temperature Climate Control Seats, heated automotive interior systems (including heated seats, steering wheels, armrests and other components), battery performance solutions, cable systems, lumbar and massage comfort solutions, valve systems, and other electronic devices. Our automotive products can be found on vehicles manufactured by nearly all the major original equipment manufacturers (“OEMs”) operating in North America and Europe, and several major OEMs in Asia. We operate in locations aligned with our major customers’ product strategies to provide locally enhanced design, integration and production capabilities. Medical products include patient temperature management systems. Our medical products can be found in hospitals throughout the world, primarily in the US, China, Germany and Brazil. The Company is also developing a number of new technologies and products that will help enable improvements to existing products, improve health, wellness and patient outcomes and will lead to new product applications for existing and new and adjacent markets. Basis of Presentation and Significant Accounting Policies The unaudited consolidated condensed financial statements included herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to those rules and regulations. The information furnished in the consolidated condensed financial statements include all adjustments (consisting of only normal, recurring adjustments) considered necessary to present fairly the results of operations, financial position and cash flows of the Company. These financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. The operating results for interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. In preparing these financial statements, management was required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on our historical experience, the terms of existing contracts, our evaluation of trends in the industry, information provided by our customers and suppliers and information available from other outside sources, as appropriate. These estimates and assumptions are subject to an inherent degree of uncertainty. We are not presently aware of any events or circumstances that would require us to update such estimates and assumptions or revise the carrying value of our assets or liabilities. Our estimates may change, however, as new events occur and additional information is obtained. As a result, actual results may differ significantly from our estimates, and any such differences may be material to our financial statements. Principles of Consolidation The consolidated condensed financial statements include the accounts of the Company, its wholly owned subsidiaries and those entities in which it has a controlling financial interest. The Company evaluates its relationship with other entities for consolidation and to identify whether such entities are variable interest entities (“VIE”) and to assess whether the Company is the primary beneficiary of such entities. Investments in entities in which Gentherm does not have control but does have the ability to exercise significant influence over operating and financial policies are accounted for under the equity method. When Gentherm does not have the ability to exercise significant influence (generally when ownership interest is less than 20 %), investments in entities are measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Variable Interest Entities The Company maintains an ownership interest in a VIE, Carrar Ltd. (“Carrar”). Carrar is a technology developer of advanced thermal management systems for the electric mobility market. The Company determined that Carrar is a VIE; however, the Company does not have a controlling financial interest or have the power to direct the activities that most significantly affect the economic performance of the investment. Therefore, the Company has concluded that it is not the primary beneficiary. Gentherm’s investment in Carrar is measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. The Carrar investment was $ 5,200 as of March 31, 2023 and December 31, 2022 , and is recorded in Other non-current assets in the consolidated condensed balance sheets. Revenue Recognition The Company has no material contract assets or contract liabilities as of March 31, 2023. The Company recognizes an asset for the incremental costs of obtaining a contract with a customer if the benefits of those costs are expected to be realized for a period greater than one year . Total capitalized costs to obtain a contract were $ 3,029 and $ 2,239 as of March 31, 2023 and December 31, 2022 , respectively. These amounts are recorded in Other non-current assets and are being amortized into Product revenues over the expected production life of the applicable program.

Acquisitions

Acquisitions	3 Months Ended
	Mar. 31, 2023
Business Combinations [Abstract]
Acquisitions	Note 2 – Acquisitions Alfmeier Präzision SE On August 1, 2022 , the Company acquired 100 % of the equity interests of Alfmeier, a global leader in automotive lumbar and massage comfort solutions and a leading provider of advanced valve systems, integrated electronics and software. The acquisition further expanded the Company's value proposition beyond thermal in comfort, health, wellness, and energy efficiency and aligned with global consumer demand for expanded offerings in vehicle passenger comfort. The total consideration transferred was $ 170,700 . The results of Alfmeier's operations are reported within the Automotive segment from the acquisition date. The acquisition was accounted for as a business combination. The following table summarizes the purchase consideration and preliminary estimated fair values of assets acquired and liabilities assumed as of the acquisition date and subsequent measurement period adjustments: Initial Allocation Measurement Period Adjustments Revised Allocation Purchase price, cash consideration, net of cash acquired $ 164,887 $ 5,813 $ 170,700 — Accounts receivable 24,988 ( 121 ) 24,867 Inventory 36,026 ( 106 ) 35,920 Prepaid expenses and other assets 20,920 ( 74 ) 20,846 Operating lease right-of-use assets 4,608 — 4,608 Property and equipment 89,942 1,242 91,184 Other intangible assets 22,668 8,791 31,459 Goodwill 43,678 ( 9,184 ) 34,494 Assumed liabilities ( 55,994 ) 975 ( 55,019 ) Deferred tax liabilities ( 21,949 ) 4,290 ( 17,659 ) Net assets acquired $ 164,887 $ 5,813 $ 170,700 During the three months ended March 31, 2023 , the Company did no t record any measurement period adjustments. The preliminary fair values of assets acquired and liabilities assumed are subject to change as the Company completes its analysis of the fair values as of the date of acquisition. The following table summarizes the preliminary allocation of the purchase consideration to the other intangible assets acquired: Preliminary Fair Value Weighted Average Life (in years) Definite-lived: Customer related $ 19,812 14 Technology 11,647 9 Total $ 31,459 Assets acquired and liabilities assumed were recorded at estimated fair values based on third-party valuations, management’s estimates, available information, and supportable assumptions that management considered reasonable. The fair value of the intangible assets was based on third-party valuations and management’s estimates, generally utilizing income and market approaches. Goodwill recognized in this transaction is primarily attributable to the Company’s expected future economic benefits from combining operations to offer more compelling and high-value solutions across complementary customer relationships as well as expected future synergies. The goodwill is not expected to be deductible for tax purposes. The following unaudited pro forma information represents our product revenues as if the acquisition of Alfmeier had occurred as of January 1, 2022: Three Months Ended March 31, 2022 Product revenues $ 333,756 Net income 8,567 Jiangmen Dacheng Medical Equipment Co. Ltd On July 13, 2022 , the Company acquired 100 % of the equity interests of Dacheng and its wholly owned subsidiary, IOB Medical, Inc. Dacheng, a privately held manufacturer of medical materials and medical equipment, including patient temperature management solutions, for numerous local and international customers. The acquisition provided Gentherm Medical a local presence in China’s high-growth market for patient warming devices and other medical device products, and expanded overall manufacturing capacity to include a low-cost manufacturing site. The total consideration transferred was $ 35,048 . The purchase agreement also included potential cash payments contingent upon the achievement of certain performance metrics and continued employment of the former majority shareholder through a series of defined dates. The achievement of these performance metrics resulted in cash payments of $ 500 . These cash payments were accounted for as compensation expense and recorded as a component of selling, general and administrative expense ratably over the service period. The acquisition was accounted for as a business combination. The following table summarizes the purchase consideration and preliminary estimated fair values of assets acquired and liabilities assumed as of the acquisition date and subsequent measurement period adjustments: Initial Allocation Measurement Period Adjustments Revised Allocation Purchase price, cash consideration, net of cash acquired $ 35,048 $ — $ 35,048 — Accounts receivable 746 ( 84 ) 662 Inventory 1,942 ( 177 ) 1,765 Prepaid expenses and other assets 152 22 174 Operating lease right-of-use assets 841 — 841 Property and equipment 684 — 684 Other intangible assets 19,094 965 20,059 Goodwill 22,995 ( 3,979 ) 19,016 Assumed liabilities ( 2,799 ) ( 40 ) ( 2,839 ) Deferred tax liabilities ( 8,607 ) 3,293 ( 5,314 ) Net assets acquired $ 35,048 $ — $ 35,048 During the three months ended March 31, 2023 , the Company did no t record any measurement period adjustments. The preliminary fair values of assets acquired and liabilities assumed are subject to change as the Company completes its analysis of the fair values as of the date of acquisition. The following table summarizes the preliminary allocation of the purchase consideration to the other intangible assets acquired: Preliminary Fair Value Weighted Average Life (in years) Definite-lived: Customer related $ 12,837 12 Technology 4,749 12 Indefinite-lived: Tradenames 2,473 — Total $ 20,059 Assets acquired and liabilities assumed were recorded at estimated fair values based on third-party valuations, management’s estimates, available information, and supportable assumptions that management considered reasonable. The fair value of the intangible assets was based on third-party valuations and management’s estimates, generally utilizing income and market approaches. Goodwill recognized in this transaction is primarily attributable to the Company’s expected future economic benefits from the enhanced access to high-growth markets including private label opportunities through Dacheng’s innovative patient temperature management devices. The goodwill is not expected to be deductible for tax purposes. The pro forma effects of this acquisition would not materially impact the Company’s reported results for any period presented, and as a result no pro forma financial statements are presented.

Restructuring and Impairments

Restructuring and Impairments	3 Months Ended
	Mar. 31, 2023
Restructuring and Related Activities [Abstract]
Restructuring and Impairments	Note 3 – Restructuring and Impairments The Company continuously monitors market developments, industry trends and changing customer needs and in response, may undertake restructuring actions, as necessary, to execute management’s strategy, streamline operations and optimize the Company’s cost structure. Restructuring actions may include the realignment of existing manufacturing footprint, facility closures, or similar actions, either in the normal course of business or pursuant to significant restructuring programs. These actions may result in employees receiving voluntary or involuntary employee termination benefits, which are mainly statutory requirements or other contractual agreements. Voluntary termination benefits are accrued when an employee accepts the related offer. Involuntary termination benefits are accrued upon the commitment to a termination plan and when the benefit arrangement is communicated to affected employees, or when liabilities are determined to be probable and estimable, depending on the existence of a substantive plan for severance or termination. Manufacturing Footprint Rationalization During 2019, the Company committed to a restructuring plan (“Plan”) to improve the Company’s manufacturing productivity and rationalize its footprint. Under this Plan, the Company relocated and consolidated certain automotive electronics manufacturing plants in North America and China. During the three months ended March 31, 2023 , the Company did no t recognize any restructuring expense. During the three months ended March 31, 2022 , the Company recognized restructuring expense of $ 50 for employee separation costs and $ 101 for other costs. The Company has recorded approximately $ 10,359 of restructuring expenses since the inception of this program and as of March 31, 2023 , $ 588 remains accrued. Other Restructuring Activities The Company has undertaken several discrete restructuring actions. During the three months ended March 31, 2023 , the Company recognized $ 1,206 for employee separation costs and $ 63 of other costs. During the three months ended March 31, 2022 , the Company recognized $ 30 for other costs. These restructuring expenses were primarily associated with restructuring actions focused on the reduction of global overhead costs. Restructuring Expenses By Reporting Segment The following table summarizes restructuring expense for the three months ended March 31, 2023 and 2022 by reporting segment: Three Months Ended March 31, 2023 2022 Automotive $ 1,074 $ 181 Medical — — Corporate 195 — Total $ 1,269 $ 181 Restructuring Liability Restructuring liabilities are classified as other current liabilities in the consolidated condensed balance sheets. The following table summarizes restructuring liability for the three months ended March 31, 2023: Employee Separation Costs Other Related Costs Total Balance at December 31, 2022 $ 588 $ — $ 588 Additions, charged to restructuring expenses 1,206 63 1,269 Cash payments — ( 63 ) ( 63 ) Currency translation 16 — 16 Balance at March 31, 2023 $ 1,810 $ — $ 1,810 Impairments – Non-Automotive Electronics Business On December 31, 2022, the Company approved a plan to exit its non-automotive electronics business to strengthen the Company’s core business and focus its resources and equipment with businesses and investments that are more strategic and profitable. The Company will continue to sell certain non-automotive electronics products until the exit is complete. During the year ended December 31, 2022, the Company recorded non-cash impairment charges of $ 9,378 , $ 5,601 and $ 690 for write downs of inventory, intangible assets and property and equipment, respectively, within the Automotive segment. During the three months ended March 31, 2023 , the Company recorded non-cash impairment charges of $ 1,419 for the write down of inventory within the Automotive segment. This charge is recorded in Cost of sales. The Company is no longer pursuing a sale of the business and intends to wind-down the operations of the business by the end of 2023, subject to discussions with customers and suppliers.

Details of Certain Balance Shee

Details of Certain Balance Sheet Components	3 Months Ended
	Mar. 31, 2023
Balance Sheet Components [Abstract]
Details of Certain Balance Sheet Components	Note 4 – Details of Certain Balance Sheet Components March 31, 2023 December 31, 2022 Other current assets: Billable tooling $ 16,296 $ 15,267 Income tax and other tax receivable 14,048 15,041 Notes receivable 13,075 12,127 Prepaid expenses 8,800 6,239 Short-term derivative financial instruments 8,548 6,564 Receivables due from factor 5,987 5,490 Other 2,937 3,869 Total other current assets $ 69,691 $ 64,597 Other current liabilities: Accrued employee liabilities $ 29,119 $ 32,031 Liabilities from discounts and rebates 26,148 26,640 Income tax and other taxes payable 16,413 14,459 Accrued warranty 2,821 2,380 Restructuring 1,810 588 Other 12,585 17,716 Total other current liabilities $ 88,896 $ 93,814

Goodwill and Other Intangibles

Goodwill and Other Intangibles	3 Months Ended
	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangibles	Note 5 – Goodwill and Other Intangibles Goodwill Changes in the carrying amount of goodwill, by reportable segment, for the three months ended March 31, 2023 was as follows: Automotive Medical Total Balance as of December 31, 2022 $ 73,069 $ 46,705 $ 119,774 Currency translation 949 232 1,181 Balance as of March 31, 2023 $ 74,018 $ 46,937 $ 120,955 Other Intangible Assets Other intangible assets and accumulated amortization balances as of March 31, 2023 and December 31, 2022 were as follows: March 31, 2023 December 31, 2022 Gross Accumulated Net Carrying Gross Accumulated Net Carrying Definite-lived: Customer relationships $ 113,909 $ ( 68,795 ) $ 45,114 $ 112,286 $ ( 65,748 ) $ 46,538 Technology 45,340 ( 26,696 ) 18,644 44,745 ( 25,709 ) 19,036 Product development costs 19,051 ( 18,884 ) 167 18,774 ( 18,456 ) 318 Software development 1,007 — 1,007 1,007 — 1,007 Indefinite-lived: Tradenames 7,119 — 7,119 7,034 — 7,034 Total $ 186,426 $ ( 114,375 ) $ 72,051 $ 183,846 $ ( 109,913 ) $ 73,933 In addition to annual impairment testing, which is performed in the fourth quarter of each fiscal year, the Company continuously monitors for events and circumstances that could negatively impact the key assumptions used in determining fair value and therefore require interim impairment testing, including long-term revenue growth projections, profitability, discount rates, recent market valuations from transactions by comparable companies, volatility in the Company's market capitalization, and general industry, market and macroeconomic conditions. We are not presently aware of any events or circumstances that would require us to revise the carrying value of our assets or liabilities as of March 31, 2023 .

Debt

Debt	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Debt	Note 6 – Debt The following table summarizes the Company’s debt as of March 31, 2023 and December 31, 2022: March 31, 2023 December 31, 2022 Interest Principal Interest Principal Credit Agreement: Revolving Credit Facility (U.S. Dollar denominations) 6.28 % $ 232,000 5.80 % $ 232,000 Other loans 3.90 % - 5.21 % 1,555 3.89 % - 5.21 % 2,011 Finance leases N/A 999 N/A 1,085 Total debt 234,554 235,096 Current maturities ( 1,996 ) ( 2,443 ) Long-term debt, less current maturities $ 232,558 $ 232,653 Credit Agreement On June 10, 2022, the Company entered into a Second Amended and Restated Credit Agreement (the “Second Amended and Restated Credit Agreement”) with a consortium of lenders and Bank of America, N.A. as administrative agent (the “Agent”). The Second Amended and Restated Credit Agreement provides for a $ 500,000 secured revolving credit facility (the “Revolving Credit Facility”), with a $ 50,000 sublimit for swing line loans and a $ 15,000 sublimit for the issuance of standby letters of credit. Any amount of the facility utilized for swing line loans or letters of credit outstanding will reduce the amount available under the Second Amended and Restated Credit Agreement. The Company had no ou tstanding letters of credit issued as of March 31, 2023 and December 31, 2022. Subject to specified conditions, Gentherm can increase the Revolving Credit Facility or incur secured term loans in an aggregate amount of up to $ 200,000 . The Second Amended and Restated Credit Agreement matures on June 10, 2027 . The U.S. borrowers and guarantors participating in the Second Amended and Restated Credit Agreement also entered into a Second Amended and Restated Pledge and Security Agreement (the “Second Amended and Restated Security Agreement”). The Second Amended and Restated Security Agreement grants a security interest to the Agent in substantially all of the personal property of the Company and its U.S. subsidiaries designated as borrowers to secure their respective obligations under the Second Amended and Restated Security Agreement, including the stock and membership interests of specified subsidiaries (limited to 66 % of the stock in the case of certain non-U.S. subsidiaries). In addition to the security obligations, all obligations under the Second Amended and Restated Credit Agreement (including all obligations of any U.S. or non-U.S. loan party) are unconditionally guaranteed by certain of Gentherm’s domestic subsidiaries, and the German subsidiary borrowers and certain other foreign subsidiaries guarantee all obligations of the non-U.S. loan parties under the Second Amended and Restated Credit Agreement. The Second Amended and Restated Credit Agreement restricts, among other things, the amount of dividend payments the Company can make to shareholders. The Second Amended and Restated Credit Agreement contains covenants, that, among other things, (i) prohibit or limit the ability of the borrowers and any material subsidiary to incur additional indebtedness, create liens, pay dividends, make certain types of investments (including acquisitions), enter into certain types of transactions with affiliates, prepay other indebtedness, sell assets or enter into certain other transactions outside the ordinary course of business, and (ii) require that Gentherm maintain a minimum Consolidated Interest Coverage Ratio and a maximum Consolidated Net Leverage Ratio (based on consolidated EBITDA for the applicable trailing four fiscal quarters) as of the end of any fiscal quarter. The Second Amended and Restated Credit Agreement also contains customary events of default. As of March 31, 2023, the Company was in compliance with the terms of the Second Amended and Restated Credit Agreement. The Second Amended and Restated Credit Agreement additionally contains customary events of default. Upon the occurrence of an event of default, the amounts outstanding under the Revolving Credit Facility may be accelerated and may become immediately due and payable. Under the Second Amended and Restated Credit Agreement, U.S. Dollar denominated loans bear interest at either a base rate (“Base Rate Loans”) or Term SOFR rate (“Term SOFR Rate Loans”), plus a margin (“Applicable Rate”). The rate for Base Rate Loans is equal to the highest of the Federal Funds Rate plus 0.50 %, Bank of America’s prime rate, or the Term SOFR rate plus 1.00 %. The rate for Term SOFR Rate Loans denominated in U.S. Dollars is equal to the forward-looking Secured Overnight Financing Rate (“SOFR”) term rate administered by the CME with a term of one month. All loans denominated in a currency other than the U.S. Dollar must be Term SOFR Rate Loans. Interest is payable at least quarterly. Additionally, a commitment fee of between 0.175 % to 0.300 %, which will vary based on the Consolidated Net Leverage Ratio, as defined in the Second Amended and Restated Credit Agreement, is payable on the average daily unused amounts under the Revolving Credit Facility. The Applicable Rate varies based on the Consolidated Net Leverage Ratio reported by the Company. As long as the Company is not in default of the terms and conditions of the Second Amended and Restated Credit Agreement, the lowest and highest possible Applicable Rate is 1.125 % and 2.125 %, respectively, for Term SOFR Rate Loans and 0.125 % and 1.125 %, respectively, for Base Rate Loans. Borrowing availability is subject to, among other things, the Company’s compliance with the minimum Consolidated Interest Coverage Ratio and the maximum Consolidated Net Leverage Ratio as of the end of any fiscal quarter. Based upon consolidated EBITDA for the trailing four fiscal quarters calculated for purposes of the Consolidated Net Leverag e Ratio, $ 266,444 r emained available as of March 31, 2023 for additional borrowings under the Second Amended and Restated Credit Agreement subject to specified conditions that Gentherm currently satisfies. In connection with the Second Amended and Restated Credit Agreement, the Company incurred debt issuance costs of $ 1,417 , which have been capitalized and will be amortized into interest expense over the term of the credit facility. The scheduled principal maturities of our debt as of March 31, 2023 were as follows: U.S. Other Debt Total 2023 $ — $ 1,892 $ 1,892 2024 — 440 440 2025 — 152 152 2026 — 70 70 2027 232,000 — 232,000 2028 — — — Total $ 232,000 $ 2,554 $ 234,554

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 7 – Commitments and Contingencies Legal and other contingencies The Company may be subject to various legal actions and claims in the ordinary course of its business, including those arising out of breach of contracts, intellectual property rights, environmental matters, regulatory matters and employment-related matters. The Company establishes accruals for matters which it believes that losses are probable and can be reasonably estimated. Although it is not possible to predict with certainty the outcome of these matters, the Company is of the opinion that the ultimate resolution of these matters will not have a material adverse effect on its consolidated condensed results of operations or financial position. Product liability and warranty reserves are recorded separately from legal reserves. Product Liability and Warranty Matters In the event that the Company’s products fail to perform as expected or result in alleged bodily injury or property damage, our products may subject us to warranty claims and product liability. If any of our products are or are alleged to be defective, we may be required to participate in a recall or other corrective action involving such products. The Company maintains liability insurance coverage at levels based on commercial norms and historical claims experience. The Company can provide no assurances that it will not experience material claims or liabilities in the future or that it will not incur significant costs to defend such claims. The Company accrues warranty obligations for products sold based on management estimates of future failure rates and current claim cost experience, with support from the sales, engineering, quality and legal functions. Using historical information available to the Company, including any claims filed by customers, the warranty accrual is adjusted quarterly to reflect management’s estimate of future claims. The following is a reconciliation of the changes in accrued warranty costs: Three Months Ended March 31, 2023 2022 Balance at the beginning of the period $ 2,380 $ 1,916 Warranty claims paid ( 559 ) ( 334 ) Warranty expense for products shipped during the current period 988 354 Adjustments to warranty estimates from prior periods ( 6 ) ( 152 ) Adjustments due to currency translation 18 ( 12 ) Balance at the end of the period $ 2,821 $ 1,772 Other matters Purchase commitments for materials, supplies, services and capital expenditures, as part of the normal course of business, are generally consistent from year to year. In addition, due to supply shortages of semiconductors, the Company has entered into agreements with various suppliers to reserve the right to purchase certain semiconductor chips over rolling periods of 12 - 24 months , with volume commitments determined based on our anticipated production requirements. As of March 31, 2023 , the Company’s total commitments for these semiconductor chip agreements was $ 40,593 . Such agreements provide the Company with priority access to semiconductor chips as they become available, however, these agreements do not guarantee that our suppliers will meet the timing and quantities requested by Gentherm. All other purchase commitments as of March 31, 2023 were immaterial.

Earnings Per Share

Earnings Per Share	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Earnings per Share	Note 8 – Earnings Per Share Basic earnings per share are computed by dividing net income by the weighted average number of shares of Common Stock outstanding during the period. The Company’s diluted earnings per share give effect to all potential shares of Common Stock outstanding during a period that do not have an anti-dilutive impact to the calculation. In computing the diluted earnings per share, the treasury stock method is used in determining the number of shares assumed to be issued from the exercise of Common Stock equivalents. The following table illustrates earnings per share and the weighted average shares outstanding used in calculating basic and diluted earnings per share: Three Months Ended March 31, 2023 2022 Net income $ 7,963 $ 11,747 Basic weighted average shares of Common Stock outstanding 33,181,828 33,034,872 Dilutive effect of stock options, restricted stock awards and restricted stock units 204,306 341,892 Diluted weighted average shares of Common Stock outstanding 33,386,134 33,376,764 Basic earnings per share $ 0.24 $ 0.36 Diluted earnings per share $ 0.24 $ 0.35 There were no shares excluded from the Company’s diluted earnings per share for the three months ended March 31, 2023 and 2022 on the basis that their inclusion would have an anti-dilutive impact on the calculation.

Financial Instruments

Financial Instruments	3 Months Ended
	Mar. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments	Note 9 – Financial Instruments Derivative Financial Instruments The Company is exposed to various market risks including, but not limited to, changes in foreign currency exchange rates, changes in interest rates and price fluctuations of certain material commodities such as copper. Market risks for changes in interest rates relate primarily to its debt obligations under the Second Amended and Restated Credit Agreement. Foreign currency exchange risks are attributable to sales to foreign customers and purchases from foreign suppliers not denominated in a location’s functional currency, foreign plant operations, intercompany indebtedness, intercompany investments and include exposures to the Euro, Mexican Peso, Canadian Dollar, Hungarian Forint, North Macedonian Denar, Ukrainian Hryvnia, Japanese Yen, Chinese Renminbi, Korean Won, Czech Koruna and Vietnamese Dong. The Company regularly enters into derivative contracts with the objective of managing its financial and operational exposure arising from these risks by offsetting gains and losses on the underlying exposures with gains and losses on the financial instruments used to hedge them. The decision of whether and when to execute derivative financial instruments, along with the duration of the instrument, may vary from period to period depending on market conditions, the relative costs of the instruments and capacity to hedge. The duration is linked to the timing of the underlying exposure, with the connection between the two being regularly monitored. The Company does not enter into derivative financial instruments for speculative or trading purposes. Some derivative contracts do not qualify for hedge accounting; for other derivative contracts, we elect to not apply hedge accounting. The Company’s designated hedging relationships are formally documented at the inception of the hedge, and hedges must be highly effective in offsetting changes to future cash flows on hedged transactions both at the inception of a hedge and on an ongoing basis to be designated for hedge accounting treatment. For derivative contracts which can be classified as a cash flow hedge, the effective portion of the change in the fair value of the derivative is recorded to Accumulated other comprehensive loss in the consolidated condensed balance sheets. When the underlying hedge transaction is realized, the gain or loss included in Accumulated other comprehensive loss is recorded in earnings in the consolidated condensed statements of income on the same line as the gain or loss on the hedged item attributable to the hedged risk. The Company records the ineffective portion of designated foreign currency and copper commodity hedging instruments, if any, to cost of sales in the consolidated condensed statements of income. Cash flows associated with derivatives are reported in net cash provided by (used in) operating activities in the Company’s consolidated condensed statements of cash flows. The Company uses an income approach to value derivative instruments, analyzing quoted market prices to calculate the forward values and then discounting such forward values to the present value using benchmark rates at commonly quoted intervals for the instrument’s full term. The Company is party to a floating-to-fixed interest rate swap agreement with a notional amount of $ 100,000 and a maturity date of July 2025 . This interest rate swap is an undesignated hedge of the Company’s exposure to interest payment fluctuations on a portion of the Revolving Credit Facility borrowings that were drawn for the acquisitions of Alfmeier and Dacheng. The periodic changes in fair value is recognized in Interest expense, net. Information related to the recurring fair value measurement of derivative instruments in our consolidated condensed balance sheet as of March 31, 2023 is as follows: Asset Derivatives Liability Derivatives Fair Value Notional Amount Balance Sheet Fair Balance Sheet Fair Net Asset/ Derivatives Designated as Cash Flow Hedges Foreign currency derivatives Level 2 $ 69,108 Other current assets $ 6,474 Other current liabilities $ — $ 6,474 Derivatives Not Designated as Hedging Instruments Interest rate contracts Level 2 $ 100,000 Other current assets $ 2,073 Other current liabilities $ — $ 2,073 Information related to the recurring fair value measurement of derivative instruments in our consolidated condensed balance sheet as of December 31, 2022 is as follows: Asset Derivatives Liability Derivatives Fair Value Notional Amount Balance Sheet Fair Balance Sheet Fair Net Asset/ Derivatives Designated as Cash Flow Hedges Foreign currency derivatives Level 2 $ 40,063 Other current assets $ 3,791 Other current liabilities $ — $ 3,791 Derivatives Not Designated as Hedging Instruments Interest rate contracts Level 2 $ 100,000 Other current assets $ 2,772 Other current liabilities $ — $ 2,772 Information relating to the effect of derivative instruments on our consolidated condensed statements of income and the consolidated condensed statements of comprehensive income is as follows: Three Months Ended March 31, Location 2023 2022 Derivatives Designated as Cash Flow Hedges Foreign currency derivatives Cost of sales – income $ 1,059 $ 153 Other comprehensive income 2,683 610 Total foreign currency derivatives $ 3,742 $ 763 Commodity derivatives Cost of sales – income $ — $ 19 Other comprehensive loss — ( 6 ) Total commodity derivatives $ — $ 13 Derivatives Not Designated as Hedging Instruments Interest rate contracts Interest income, net $ ( 699 ) $ — Total interest rate derivatives $ ( 699 ) $ — The Company did no t incur any hedge ineffectiveness during the three months ended March 31, 2023 and 2022. Accounts Receivable Factoring The Company sells certain customer trade receivables on a non-recourse basis under factoring arrangements with designated financial institutions. The sale of receivables under these agreements is considered an off-balance sheet arrangement to the Company and is accounted for as a true sale and excluded from accounts receivable in the consolidated condensed balance sheets. These factoring arrangements include a deferred purchase price component in which a portion of the purchase price for the receivable is paid by the financial institution in cash upon sale and the remaining portion is recorded as a deferred purchase price receivable and paid at a later date. Deferred purchase price receivables are recorded in Other current assets within the consolidated condensed balance sheets. Cash proceeds received upon the sale of the receivables are included in net cash provided by (used in) operating activities and the cash proceeds received on the deferred purchase price receivables are included in cash provided by investing activities. All factoring arrangements incorporate customary representations, including representations as to validity of amounts due, completeness of performance obligations and absence of commercial disputes. Receivables factored and availability under receivables factoring agreements balances as of March 31, 2023 and December 31, 2022 were as follows: March 31, 2023 December 31, 2022 Receivables factored and outstanding $ 21,034 $ 19,108 Amount available under the credit limit 3,321 5,034 Collective factoring limit $ 24,355 $ 24,142 Trade receivables sold and factoring fees incurred during the three months ended March 31, 2023 and 2022 were as follows: Three Months Ended March 31, 2023 2022 Trade receivables sold $ 38,540 $ — Factoring fees incurred 161 —

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 10 – Fair Value Measurements Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Fair value measurements are based on one or more of the following three valuation techniques: Market : This approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. Income : This approach uses valuation techniques to convert future amounts to a single present value amount based on current market expectations. Cost : This approach is based on the amount that would be required to replace the service capacity of an asset (replacement cost). The Company uses the following fair value hierarchy to measure fair value into three broad levels, which are described below: Level 1 : Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2 : Inputs, other than quoted market prices included in Level 1, that are observable either directly or indirectly for the asset or liability. Level 3 : Unobservable inputs that are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. Items Measured at Fair Value on a Recurring Basis Except for derivative instruments (see Note 9) and pension plan assets, the Company had no material financial assets and liabilities that were carried at fair value at March 31, 2023 and December 31, 2022. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and also considers counterparty credit risk in its assessment of fair value. Items Measured at Fair Value on a Nonrecurring Basis The Company measures certain assets and liabilities at fair value on a non-recurring basis. As these nonrecurring fair value measurements are generally determined using unobservable inputs, these fair value measurements are classified within Level 3 of the fair value hierarchy. The Company utilized a third-party to assist in the Level 3 fair value estimates of other intangible assets for recent acquisitions (see Note 2). The estimated fair values of these assets were based on third-party valuations and management’s estimates, generally utilizing income and market approaches. As of March 31, 2023, and December 31, 2022 , there were no other significant assets or liabilities measured at fair value on a non-recurring basis. Items Not Carried at Fair Value The Company uses an income valuation technique to measure the fair values of its debt instruments by converting amounts of future cash flows to a single present value amount using rates based on current market expectations (Level 2 inputs). As of March 31, 2023, and December 31, 2022 , the carrying values of the indebtedness under the Company’s Second Amended and Restated Credit Agreement were not materially different than the estimated fair values because the interest rates on variable rate debt approximated rates currently available to the Company (see Note 6).

Equity

Equity	3 Months Ended
	Mar. 31, 2023
Stockholders' Equity Note [Abstract]
Equity	Note 11 – Equity In December 2020, the Board of Directors of Gentherm Incorporated (“Board of Directors”) authorized a stock repurchase program (the “2020 Stock Repurchase Program”). Under the 2020 Stock Repurchase Program, the Company is authorized to repurchase up to $ 150,000 of its issued and outstanding common stock over a three-year period, expiring December 15, 2023 . Repurchases may be made, from time to time, in amounts and at prices the Company deems appropriate, subject to market conditions, applicable legal requirements, debt covenants and other considerations. Any such repurchases may be executed using open market purchases, privately negotiated agreements or other transactions. Repurchases may be funded from cash on hand, available borrowings or proceeds from potential debt or other capital markets sources. During the three months ended March 31, 2023 , the Company repurchased $ 9,997 of shares under the 2020 Stock Repurchase Program with an average price paid per share of $ 59.27 . The 2020 Stock Repurchase Program had $ 120,003 of repurchase authorization remaining as of March 31, 2023 .

Reclassifications Out of Accumu

Reclassifications Out of Accumulated Other Comprehensive Income (Loss)	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Reclassifications Out of Accumulated Other Comprehensive Income (Loss)	Note 12 – Reclassifications Out of Accumulated Other Comprehensive Income (Loss) Reclassification adjustments and other activities impacting Accumulated other comprehensive loss during the three months ended March 31, 2023 and 2022 were as follows: Defined Foreign Foreign Commodity Hedge Total Balance at December 31, 2022 $ ( 1,067 ) $ ( 48,269 ) $ 2,847 $ — $ ( 46,489 ) Other comprehensive income before reclassifications — 8,191 3,742 — 11,933 Income tax effect of other comprehensive income before reclassifications — 64 ( 815 ) — ( 751 ) Amounts reclassified from accumulated other comprehensive income into net income 6 — ( 1,059 ) a — a ( 1,053 ) Income taxes reclassified into net income ( 2 ) — 261 — 259 Net current period other comprehensive income 4 8,255 2,129 — 10,388 Balance at March 31, 2023 $ ( 1,063 ) $ ( 40,014 ) $ 4,976 $ — $ ( 36,101 ) (a) The amounts reclassified from accumulated other comprehensive loss were included in cost of sales. Defined Foreign Foreign Commodity Hedge Total Balance at December 31, 2021 $ ( 2,893 ) $ ( 34,188 ) $ 154 $ 5 $ ( 36,922 ) Other comprehensive (loss) income before reclassifications — ( 9,154 ) 763 13 ( 8,378 ) Income tax effect of other comprehensive loss before reclassifications — ( 140 ) ( 179 ) ( 3 ) ( 322 ) Amounts reclassified from accumulated other comprehensive loss into net income 35 — ( 153 ) a ( 19 ) a ( 137 ) Income taxes reclassified into net income ( 6 ) — 33 4 31 Net current period other comprehensive income (loss) 29 ( 9,294 ) 464 ( 5 ) ( 8,806 ) Balance at March 31, 2022 $ ( 2,864 ) $ ( 43,482 ) $ 618 $ — $ ( 45,728 ) (a) The amounts reclassified from accumulated other comprehensive loss were included in cost of sales. The Company expects all of the existing gains and losses related to foreign currency derivatives reported in Accumulated other comprehensive loss as of March 31, 2023 to be reclassified into earnings during the next twelve months. See Note 9 for additional information about derivative financial instruments and the effects from reclassification to net income.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Note 13 – Income Taxes At the end of each interim period, the Company makes an estimate of the annual expected effective income tax rate and applies that rate to its ordinary year-to-date earnings or loss. The income tax provision or benefit related to unusual or infrequent items, if applicable, that will be separately reported or reported net of their related tax effects are individually computed and recognized in the interim period in which those items occur. In addition, the effect of changes in enacted tax laws or rates, tax status, judgment on the realizability of a beginning-of-the-year deferred tax asset in future years or income tax contingencies is recognized in the interim period in which the change occurs. The computation of the annual expected effective income tax rate at each interim period requires certain estimates and assumptions including, but not limited to, the expected pre-tax income (or loss) for the year, projections of the proportion of income (and/or loss) earned and taxed in respective jurisdictions, permanent and temporary differences, and the likelihood of the realizability of deferred tax assets generated in the current year. Jurisdictions with a projected loss for the year for which no tax benefit can be recognized due to a valuation allowance are excluded from the estimated annual effective tax rate. The impact of such an exclusion could result in a higher or lower effective tax rate during a particular quarter, based upon the composition and timing of actual earnings compared to annual projections. The estimates used to compute the provision or benefit for income taxes may change as new events occur, additional information is obtained or as our tax environment changes. To the extent that the expected annual effective income tax rate changes, the effect of the change on prior interim periods is included in the income tax provision in the period in which the change in estimate occurs. A summary of the provision for income taxes and the corresponding effective tax rate for the three months ended March 31, 2023 and 2022, is shown below: Three Months Ended March 31, 2023 2022 Income tax expense $ 3,728 $ 4,295 Earnings before income tax $ 11,691 $ 16,042 Effective tax rate 31.9 % 26.8 % Income tax expense was $ 3,728 for the three months ended March 31, 2023 on earnings before income tax of $ 11,691 , representing an effective tax rate of 31.9 % . The tax amount included the effect of the settlement and closure of a multi-year state audit of $ 454 . Adjusted for the audit impacts, the effective rate was 28.0 %. The effective tax rate differed from the U.S. Federal statutory rate of 21.0 % primarily due to the impact of income taxes on foreign earnings taxed at rates varying from the U.S. statutory rate, the unfavorable impact of the global intangible low-tax income (“GILTI”), and the quarterly accrual for uncertain tax positions, partially offset by the impact of research and development credits in various jurisdictions and certain favorable tax effects on stock compensation vesting. Income tax expense was $ 4,295 for the three months ended March 31, 2022 on earnings before income tax of $ 16,042 representing an effective tax rate of 26.8 %. The effective tax rate differed from the U.S. Federal statutory rate of 21.0 % primarily due to the impact of income taxes on foreign earnings taxed at rates varying from the U.S. statutory rate, the unfavorable impact of the GILTI, and the quarterly accrual for uncertain tax positions, partially offset by the impact of certain favorable tax effects on stock compensation vesting.

Segment Reporting

Segment Reporting	3 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
Segment Reporting	Note 14 – Segment Reporting Segment information is used by management for making operating decisions for the Company. Management evaluates the performance of the Company’s segments based primarily on operating income or loss. The Company’s reportable segments are as follows: • Automotive – this segment represents the design, development, manufacturing and sales of automotive climate comfort systems, automotive cable systems, lumbar and massage comfort solutions, valve systems, battery performance solutions, and automotive electronic and software systems. • Medical – this segment represents the results from our patient temperature management business within the medical industry. The Corporate category includes unallocated costs related to our corporate headquarter activities, including selling, general and administrative costs and acquisition transaction costs, which do not meet the requirements for being classified as an operating segment. The tables below present segment information about the reported product revenues, depreciation and amortization and operating income (loss) of the Company for three months ended March 31, 2023 and 2022. Three Months Ended March 31, Automotive Medical Corporate Total 2023 Product revenues $ 352,692 $ 10,933 $ — $ 363,625 Depreciation and amortization 12,290 978 265 $ 13,583 Operating income (loss) 38,379 ( 493 ) ( 20,212 ) $ 17,674 2022 Product revenues $ 257,864 $ 9,793 $ — $ 267,657 Depreciation and amortization 8,667 604 306 $ 9,577 Operating income (loss) 31,275 ( 851 ) ( 16,234 ) $ 14,190 Automotive and Medical segment product revenues by product category for the three months ended March 31, 2023 and 2022 were as follows: Three Months Ended March 31, 2023 2022 Climate Control Seat $ 114,753 $ 102,734 Seat Heaters 75,636 68,896 Lumbar and Massage Comfort Solutions (a) 38,738 — Steering Wheel Heaters 36,347 28,736 Valve Systems (a) 26,994 — Battery Performance Solutions 20,309 17,613 Automotive Cables 20,220 22,045 Electronics 10,970 10,828 Other Automotive 8,725 7,012 Subtotal Automotive segment 352,692 257,864 Medical segment (b) 10,933 9,793 Total Company $ 363,625 $ 267,657 (a) Represents product revenues from Alfmeier (acquired on August 1, 2022) - (see Note 2) (b) Includes product revenues of $ 1,279 from Dacheng (acquired on July 13, 2022) - (see Note 2) Total product revenues information by geographic area for the three months ended March 31, 2023 and 2022 is as follows (based on shipment destination): Three Months Ended March 31, 2023 2022 United States $ 141,452 $ 104,122 China 46,654 38,353 South Korea 28,738 21,175 Germany 26,512 19,786 Czech Republic 17,650 10,808 Japan 15,222 11,816 Romania 12,533 12,755 Slovakia 11,596 8,536 Finland 10,133 7,893 Mexico 9,094 4,547 Other 44,041 27,866 Total Non-U.S. 222,173 163,535 Total Company $ 363,625 $ 267,657

New Accounting Pronouncements (

New Accounting Pronouncements (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	Basis of Presentation and Significant Accounting Policies The unaudited consolidated condensed financial statements included herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to those rules and regulations. The information furnished in the consolidated condensed financial statements include all adjustments (consisting of only normal, recurring adjustments) considered necessary to present fairly the results of operations, financial position and cash flows of the Company. These financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. The operating results for interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. In preparing these financial statements, management was required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on our historical experience, the terms of existing contracts, our evaluation of trends in the industry, information provided by our customers and suppliers and information available from other outside sources, as appropriate. These estimates and assumptions are subject to an inherent degree of uncertainty. We are not presently aware of any events or circumstances that would require us to update such estimates and assumptions or revise the carrying value of our assets or liabilities. Our estimates may change, however, as new events occur and additional information is obtained. As a result, actual results may differ significantly from our estimates, and any such differences may be material to our financial statements.
Principles of Consolidation	Principles of Consolidation The consolidated condensed financial statements include the accounts of the Company, its wholly owned subsidiaries and those entities in which it has a controlling financial interest. The Company evaluates its relationship with other entities for consolidation and to identify whether such entities are variable interest entities (“VIE”) and to assess whether the Company is the primary beneficiary of such entities. Investments in entities in which Gentherm does not have control but does have the ability to exercise significant influence over operating and financial policies are accounted for under the equity method. When Gentherm does not have the ability to exercise significant influence (generally when ownership interest is less than 20 %), investments in entities are measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer.
Variable Interest Entities	Variable Interest Entities The Company maintains an ownership interest in a VIE, Carrar Ltd. (“Carrar”). Carrar is a technology developer of advanced thermal management systems for the electric mobility market. The Company determined that Carrar is a VIE; however, the Company does not have a controlling financial interest or have the power to direct the activities that most significantly affect the economic performance of the investment. Therefore, the Company has concluded that it is not the primary beneficiary. Gentherm’s investment in Carrar is measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. The Carrar investment was $ 5,200 as of March 31, 2023 and December 31, 2022 , and is recorded in Other non-current assets in the consolidated condensed balance sheets.
Revenue Recognition	Revenue Recognition The Company has no material contract assets or contract liabilities as of March 31, 2023. The Company recognizes an asset for the incremental costs of obtaining a contract with a customer if the benefits of those costs are expected to be realized for a period greater than one year . Total capitalized costs to obtain a contract were $ 3,029 and $ 2,239 as of March 31, 2023 and December 31, 2022 , respectively. These amounts are recorded in Other non-current assets and are being amortized into Product revenues over the expected production life of the applicable program.

Acquisitions (Tables)

Acquisitions (Tables)	3 Months Ended
	Mar. 31, 2023
Alfmeier
Business Acquisition [Line Items]
Summary of Purchase Consideration and Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed	The following table summarizes the purchase consideration and preliminary estimated fair values of assets acquired and liabilities assumed as of the acquisition date and subsequent measurement period adjustments: Initial Allocation Measurement Period Adjustments Revised Allocation Purchase price, cash consideration, net of cash acquired $ 164,887 $ 5,813 $ 170,700 — Accounts receivable 24,988 ( 121 ) 24,867 Inventory 36,026 ( 106 ) 35,920 Prepaid expenses and other assets 20,920 ( 74 ) 20,846 Operating lease right-of-use assets 4,608 — 4,608 Property and equipment 89,942 1,242 91,184 Other intangible assets 22,668 8,791 31,459 Goodwill 43,678 ( 9,184 ) 34,494 Assumed liabilities ( 55,994 ) 975 ( 55,019 ) Deferred tax liabilities ( 21,949 ) 4,290 ( 17,659 ) Net assets acquired $ 164,887 $ 5,813 $ 170,700
Summary of Preliminary Allocation of Purchase Consideration to Other Intangible Assets Acquired	The following table summarizes the preliminary allocation of the purchase consideration to the other intangible assets acquired: Preliminary Fair Value Weighted Average Life (in years) Definite-lived: Customer related $ 19,812 14 Technology 11,647 9 Total $ 31,459
Summary of Unaudited Pro Forma Information	The following unaudited pro forma information represents our product revenues as if the acquisition of Alfmeier had occurred as of January 1, 2022: Three Months Ended March 31, 2022 Product revenues $ 333,756 Net income 8,567
Dacheng
Business Acquisition [Line Items]
Summary of Purchase Consideration and Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed	The following table summarizes the purchase consideration and preliminary estimated fair values of assets acquired and liabilities assumed as of the acquisition date and subsequent measurement period adjustments: Initial Allocation Measurement Period Adjustments Revised Allocation Purchase price, cash consideration, net of cash acquired $ 35,048 $ — $ 35,048 — Accounts receivable 746 ( 84 ) 662 Inventory 1,942 ( 177 ) 1,765 Prepaid expenses and other assets 152 22 174 Operating lease right-of-use assets 841 — 841 Property and equipment 684 — 684 Other intangible assets 19,094 965 20,059 Goodwill 22,995 ( 3,979 ) 19,016 Assumed liabilities ( 2,799 ) ( 40 ) ( 2,839 ) Deferred tax liabilities ( 8,607 ) 3,293 ( 5,314 ) Net assets acquired $ 35,048 $ — $ 35,048
Summary of Preliminary Allocation of Purchase Consideration to Other Intangible Assets Acquired	The following table summarizes the preliminary allocation of the purchase consideration to the other intangible assets acquired: Preliminary Fair Value Weighted Average Life (in years) Definite-lived: Customer related $ 12,837 12 Technology 4,749 12 Indefinite-lived: Tradenames 2,473 — Total $ 20,059

Restructuring and Impairments (

Restructuring and Impairments (Tables)	3 Months Ended
	Mar. 31, 2023
Restructuring and Related Activities [Abstract]
Summary of Restructuring Expense by Reportable Segment	The following table summarizes restructuring expense for the three months ended March 31, 2023 and 2022 by reporting segment: Three Months Ended March 31, 2023 2022 Automotive $ 1,074 $ 181 Medical — — Corporate 195 — Total $ 1,269 $ 181
Summary of Restructuring Liability	Restructuring liabilities are classified as other current liabilities in the consolidated condensed balance sheets. The following table summarizes restructuring liability for the three months ended March 31, 2023: Employee Separation Costs Other Related Costs Total Balance at December 31, 2022 $ 588 $ — $ 588 Additions, charged to restructuring expenses 1,206 63 1,269 Cash payments — ( 63 ) ( 63 ) Currency translation 16 — 16 Balance at March 31, 2023 $ 1,810 $ — $ 1,810

Details of Certain Balance Sh_2

Details of Certain Balance Sheet Components (Tables)	3 Months Ended
	Mar. 31, 2023
Balance Sheet Components [Abstract]
Summary of Certain Balance Sheet Components	March 31, 2023 December 31, 2022 Other current assets: Billable tooling $ 16,296 $ 15,267 Income tax and other tax receivable 14,048 15,041 Notes receivable 13,075 12,127 Prepaid expenses 8,800 6,239 Short-term derivative financial instruments 8,548 6,564 Receivables due from factor 5,987 5,490 Other 2,937 3,869 Total other current assets $ 69,691 $ 64,597 Other current liabilities: Accrued employee liabilities $ 29,119 $ 32,031 Liabilities from discounts and rebates 26,148 26,640 Income tax and other taxes payable 16,413 14,459 Accrued warranty 2,821 2,380 Restructuring 1,810 588 Other 12,585 17,716 Total other current liabilities $ 88,896 $ 93,814

Goodwill and Other Intangibles

Goodwill and Other Intangibles (Tables)	3 Months Ended
	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Changes in the Carrying Amount of Goodwill, By Reportable Segment	Changes in the carrying amount of goodwill, by reportable segment, for the three months ended March 31, 2023 was as follows: Automotive Medical Total Balance as of December 31, 2022 $ 73,069 $ 46,705 $ 119,774 Currency translation 949 232 1,181 Balance as of March 31, 2023 $ 74,018 $ 46,937 $ 120,955
Summary of Other Intangible Assets and Accumulated Amortization Balances	Other intangible assets and accumulated amortization balances as of March 31, 2023 and December 31, 2022 were as follows: March 31, 2023 December 31, 2022 Gross Accumulated Net Carrying Gross Accumulated Net Carrying Definite-lived: Customer relationships $ 113,909 $ ( 68,795 ) $ 45,114 $ 112,286 $ ( 65,748 ) $ 46,538 Technology 45,340 ( 26,696 ) 18,644 44,745 ( 25,709 ) 19,036 Product development costs 19,051 ( 18,884 ) 167 18,774 ( 18,456 ) 318 Software development 1,007 — 1,007 1,007 — 1,007 Indefinite-lived: Tradenames 7,119 — 7,119 7,034 — 7,034 Total $ 186,426 $ ( 114,375 ) $ 72,051 $ 183,846 $ ( 109,913 ) $ 73,933

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Summary of Company's Debt	The following table summarizes the Company’s debt as of March 31, 2023 and December 31, 2022: March 31, 2023 December 31, 2022 Interest Principal Interest Principal Credit Agreement: Revolving Credit Facility (U.S. Dollar denominations) 6.28 % $ 232,000 5.80 % $ 232,000 Other loans 3.90 % - 5.21 % 1,555 3.89 % - 5.21 % 2,011 Finance leases N/A 999 N/A 1,085 Total debt 234,554 235,096 Current maturities ( 1,996 ) ( 2,443 ) Long-term debt, less current maturities $ 232,558 $ 232,653
Principal Maturities of Debt	The scheduled principal maturities of our debt as of March 31, 2023 were as follows: U.S. Other Debt Total 2023 $ — $ 1,892 $ 1,892 2024 — 440 440 2025 — 152 152 2026 — 70 70 2027 232,000 — 232,000 2028 — — — Total $ 232,000 $ 2,554 $ 234,554

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Reconciliation of Changes in Accrued Warranty Costs	The following is a reconciliation of the changes in accrued warranty costs: Three Months Ended March 31, 2023 2022 Balance at the beginning of the period $ 2,380 $ 1,916 Warranty claims paid ( 559 ) ( 334 ) Warranty expense for products shipped during the current period 988 354 Adjustments to warranty estimates from prior periods ( 6 ) ( 152 ) Adjustments due to currency translation 18 ( 12 ) Balance at the end of the period $ 2,821 $ 1,772

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Earnings per Share and Weighted Average Shares Outstanding Used in Calculating Basic and Diluted Earnings per Share	The following table illustrates earnings per share and the weighted average shares outstanding used in calculating basic and diluted earnings per share: Three Months Ended March 31, 2023 2022 Net income $ 7,963 $ 11,747 Basic weighted average shares of Common Stock outstanding 33,181,828 33,034,872 Dilutive effect of stock options, restricted stock awards and restricted stock units 204,306 341,892 Diluted weighted average shares of Common Stock outstanding 33,386,134 33,376,764 Basic earnings per share $ 0.24 $ 0.36 Diluted earnings per share $ 0.24 $ 0.35

Financial Instruments (Tables)

Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Information Related to Recurring Fair Value Measurement of Derivative Instruments in Our Consolidated Condensed Balance Sheet	Information related to the recurring fair value measurement of derivative instruments in our consolidated condensed balance sheet as of March 31, 2023 is as follows: Asset Derivatives Liability Derivatives Fair Value Notional Amount Balance Sheet Fair Balance Sheet Fair Net Asset/ Derivatives Designated as Cash Flow Hedges Foreign currency derivatives Level 2 $ 69,108 Other current assets $ 6,474 Other current liabilities $ — $ 6,474 Derivatives Not Designated as Hedging Instruments Interest rate contracts Level 2 $ 100,000 Other current assets $ 2,073 Other current liabilities $ — $ 2,073 Information related to the recurring fair value measurement of derivative instruments in our consolidated condensed balance sheet as of December 31, 2022 is as follows: Asset Derivatives Liability Derivatives Fair Value Notional Amount Balance Sheet Fair Balance Sheet Fair Net Asset/ Derivatives Designated as Cash Flow Hedges Foreign currency derivatives Level 2 $ 40,063 Other current assets $ 3,791 Other current liabilities $ — $ 3,791 Derivatives Not Designated as Hedging Instruments Interest rate contracts Level 2 $ 100,000 Other current assets $ 2,772 Other current liabilities $ — $ 2,772
Information Related to Effect of Derivative Instruments on Our Consolidated Condensed Statements of Income and Consolidated Condensed Statements of Comprehensive Income (Loss)	Information relating to the effect of derivative instruments on our consolidated condensed statements of income and the consolidated condensed statements of comprehensive income is as follows: Three Months Ended March 31, Location 2023 2022 Derivatives Designated as Cash Flow Hedges Foreign currency derivatives Cost of sales – income $ 1,059 $ 153 Other comprehensive income 2,683 610 Total foreign currency derivatives $ 3,742 $ 763 Commodity derivatives Cost of sales – income $ — $ 19 Other comprehensive loss — ( 6 ) Total commodity derivatives $ — $ 13 Derivatives Not Designated as Hedging Instruments Interest rate contracts Interest income, net $ ( 699 ) $ — Total interest rate derivatives $ ( 699 ) $ —
Summary of Receivables Factored and Availability Under Receivables Factoring Agreements	Receivables factored and availability under receivables factoring agreements balances as of March 31, 2023 and December 31, 2022 were as follows: March 31, 2023 December 31, 2022 Receivables factored and outstanding $ 21,034 $ 19,108 Amount available under the credit limit 3,321 5,034 Collective factoring limit $ 24,355 $ 24,142
Summary of Trade Receivables Sold and Factoring Fees Incurred	Trade receivables sold and factoring fees incurred during the three months ended March 31, 2023 and 2022 were as follows: Three Months Ended March 31, 2023 2022 Trade receivables sold $ 38,540 $ — Factoring fees incurred 161 —

Reclassifications Out of Accu_2

Reclassifications Out of Accumulated Other Comprehensive Income (Loss) (Tables)	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Schedule of Reclassification Adjustments and Other Activities Impacting Accumulated Other Comprehensive Loss	Reclassification adjustments and other activities impacting Accumulated other comprehensive loss during the three months ended March 31, 2023 and 2022 were as follows: Defined Foreign Foreign Commodity Hedge Total Balance at December 31, 2022 $ ( 1,067 ) $ ( 48,269 ) $ 2,847 $ — $ ( 46,489 ) Other comprehensive income before reclassifications — 8,191 3,742 — 11,933 Income tax effect of other comprehensive income before reclassifications — 64 ( 815 ) — ( 751 ) Amounts reclassified from accumulated other comprehensive income into net income 6 — ( 1,059 ) a — a ( 1,053 ) Income taxes reclassified into net income ( 2 ) — 261 — 259 Net current period other comprehensive income 4 8,255 2,129 — 10,388 Balance at March 31, 2023 $ ( 1,063 ) $ ( 40,014 ) $ 4,976 $ — $ ( 36,101 ) (a) The amounts reclassified from accumulated other comprehensive loss were included in cost of sales. Defined Foreign Foreign Commodity Hedge Total Balance at December 31, 2021 $ ( 2,893 ) $ ( 34,188 ) $ 154 $ 5 $ ( 36,922 ) Other comprehensive (loss) income before reclassifications — ( 9,154 ) 763 13 ( 8,378 ) Income tax effect of other comprehensive loss before reclassifications — ( 140 ) ( 179 ) ( 3 ) ( 322 ) Amounts reclassified from accumulated other comprehensive loss into net income 35 — ( 153 ) a ( 19 ) a ( 137 ) Income taxes reclassified into net income ( 6 ) — 33 4 31 Net current period other comprehensive income (loss) 29 ( 9,294 ) 464 ( 5 ) ( 8,806 ) Balance at March 31, 2022 $ ( 2,864 ) $ ( 43,482 ) $ 618 $ — $ ( 45,728 ) (a) The amounts reclassified from accumulated other comprehensive loss were included in cost of sales.

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended
	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Summary of Provision for Income Taxes and Corresponding Effective Tax Rate	A summary of the provision for income taxes and the corresponding effective tax rate for the three months ended March 31, 2023 and 2022, is shown below: Three Months Ended March 31, 2023 2022 Income tax expense $ 3,728 $ 4,295 Earnings before income tax $ 11,691 $ 16,042 Effective tax rate 31.9 % 26.8 %

Segment Reporting (Tables)

Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
Segment Information about Reported Product Revenues, Depreciation and Amortization and Operating Income (Loss)	The tables below present segment information about the reported product revenues, depreciation and amortization and operating income (loss) of the Company for three months ended March 31, 2023 and 2022. Three Months Ended March 31, Automotive Medical Corporate Total 2023 Product revenues $ 352,692 $ 10,933 $ — $ 363,625 Depreciation and amortization 12,290 978 265 $ 13,583 Operating income (loss) 38,379 ( 493 ) ( 20,212 ) $ 17,674 2022 Product revenues $ 257,864 $ 9,793 $ — $ 267,657 Depreciation and amortization 8,667 604 306 $ 9,577 Operating income (loss) 31,275 ( 851 ) ( 16,234 ) $ 14,190
Segment Information About Reported Segment Product Revenues by Product Category	Automotive and Medical segment product revenues by product category for the three months ended March 31, 2023 and 2022 were as follows: Three Months Ended March 31, 2023 2022 Climate Control Seat $ 114,753 $ 102,734 Seat Heaters 75,636 68,896 Lumbar and Massage Comfort Solutions (a) 38,738 — Steering Wheel Heaters 36,347 28,736 Valve Systems (a) 26,994 — Battery Performance Solutions 20,309 17,613 Automotive Cables 20,220 22,045 Electronics 10,970 10,828 Other Automotive 8,725 7,012 Subtotal Automotive segment 352,692 257,864 Medical segment (b) 10,933 9,793 Total Company $ 363,625 $ 267,657 (a) Represents product revenues from Alfmeier (acquired on August 1, 2022) - (see Note 2) (b) Includes product revenues of $ 1,279 from Dacheng (acquired on July 13, 2022) - (see Note 2)
Product Revenues Information by Geographic Area	Total product revenues information by geographic area for the three months ended March 31, 2023 and 2022 is as follows (based on shipment destination): Three Months Ended March 31, 2023 2022 United States $ 141,452 $ 104,122 China 46,654 38,353 South Korea 28,738 21,175 Germany 26,512 19,786 Czech Republic 17,650 10,808 Japan 15,222 11,816 Romania 12,533 12,755 Slovakia 11,596 8,536 Finland 10,133 7,893 Mexico 9,094 4,547 Other 44,041 27,866 Total Non-U.S. 222,173 163,535 Total Company $ 363,625 $ 267,657

Overview - Additional Informati

Overview - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Investment amount	$ 5,200	$ 5,200
Capitalized costs to obtain contract	$ 3,029	$ 2,239
Entities Ownership Interest
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Ownership interest	20%
Minimum
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Expected period of costs to be realized to recognize assets	1 year

Acquisitions - Additional Infor

Acquisitions - Additional Information (Detail) - USD ($)	Aug. 01, 2022	Jul. 13, 2022	Mar. 31, 2023
Alfmeier
Business Acquisition [Line Items]
Acquisition date	Aug. 01, 2022
Percentage of equity interests acquired	100%
Total consideration	$ 170,700,000
Net assets acquired			$ 170,700,000
Alfmeier | Measurement Period Adjustments
Business Acquisition [Line Items]
Net assets acquired	$ 5,813,000		0
Dacheng
Business Acquisition [Line Items]
Acquisition date		Jul. 13, 2022
Percentage of equity interests acquired		100%
Total consideration		$ 35,048,000
Contingent payments		$ 500,000
Net assets acquired			35,048,000
Dacheng | Measurement Period Adjustments
Business Acquisition [Line Items]
Net assets acquired			$ 0

Acquisitions - Summary of Purch

Acquisitions - Summary of Purchase Consideration and Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed (Detail) - USD ($)			3 Months Ended
	Aug. 01, 2022	Jul. 13, 2022	Mar. 31, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Goodwill			$ 120,955,000	$ 119,774,000
Alfmeier
Business Acquisition [Line Items]
Purchase price, cash consideration, net of cash acquired			170,700,000
Accounts receivable			24,867,000
Inventory			35,920,000
Prepaid expenses and other assets			20,846,000
Operating lease right-of-use assets			4,608,000
Property and equipment			91,184,000
Other intangible assets	$ 31,459,000		31,459,000
Goodwill			34,494,000
Assumed liabilities			(55,019,000)
Deferred tax liabilities			(17,659,000)
Net assets acquired			170,700,000
Alfmeier | Initial Allocation
Business Acquisition [Line Items]
Purchase price, cash consideration, net of cash acquired	164,887,000
Accounts receivable	24,988,000
Inventory	36,026,000
Prepaid expenses and other assets	20,920,000
Operating lease right-of-use assets	4,608,000
Property and equipment	89,942,000
Other intangible assets	22,668,000
Goodwill	43,678,000
Assumed liabilities	(55,994,000)
Deferred tax liabilities	(21,949,000)
Net assets acquired	164,887,000
Alfmeier | Measurement Period Adjustments
Business Acquisition [Line Items]
Purchase price, cash consideration, net of cash acquired	5,813,000
Accounts receivable	(121,000)
Inventory	(106,000)
Prepaid expenses and other assets	(74,000)
Property and equipment	1,242,000
Other intangible assets	8,791,000
Goodwill	(9,184,000)
Assumed liabilities	975,000
Deferred tax liabilities	4,290,000
Net assets acquired	$ 5,813,000		0
Dacheng
Business Acquisition [Line Items]
Purchase price, cash consideration, net of cash acquired			35,048,000
Accounts receivable			662,000
Inventory			1,765,000
Prepaid expenses and other assets			174,000
Operating lease right-of-use assets			841,000
Property and equipment			684,000
Other intangible assets		$ 20,059,000	20,059,000
Goodwill			19,016,000
Assumed liabilities			(2,839,000)
Deferred tax liabilities			(5,314,000)
Net assets acquired			35,048,000
Dacheng | Initial Allocation
Business Acquisition [Line Items]
Purchase price, cash consideration, net of cash acquired		35,048,000
Accounts receivable		746,000
Inventory		1,942,000
Prepaid expenses and other assets		152,000
Operating lease right-of-use assets		841,000
Property and equipment		684,000
Other intangible assets		19,094,000
Goodwill		22,995,000
Assumed liabilities		(2,799,000)
Deferred tax liabilities		(8,607,000)
Net assets acquired		35,048,000
Dacheng | Measurement Period Adjustments
Business Acquisition [Line Items]
Accounts receivable		(84,000)
Inventory		(177,000)
Prepaid expenses and other assets		22,000
Other intangible assets		965,000
Goodwill		(3,979,000)
Assumed liabilities		(40,000)
Deferred tax liabilities		$ 3,293,000
Net assets acquired			$ 0

Acquisitions - Summary of Preli

Acquisitions - Summary of Preliminary Allocation of Purchase Consideration to Other Intangible Assets Acquired (Detail) - USD ($) $ in Thousands	Aug. 01, 2022	Jul. 13, 2022	Mar. 31, 2023
Alfmeier
Business Acquisition [Line Items]
Preliminary Fair Value, Total	$ 31,459		$ 31,459
Alfmeier | Customer Related
Business Acquisition [Line Items]
Preliminary Fair Value, Definite-lived	$ 19,812
Weighted Average Life (in years)	14 years
Alfmeier | Technology
Business Acquisition [Line Items]
Preliminary Fair Value, Definite-lived	$ 11,647
Weighted Average Life (in years)	9 years
Dacheng
Business Acquisition [Line Items]
Preliminary Fair Value, Total		$ 20,059	$ 20,059
Dacheng | Tradenames
Business Acquisition [Line Items]
Preliminary Fair Value, Indefinite-lived		2,473
Dacheng | Customer Related
Business Acquisition [Line Items]
Preliminary Fair Value, Definite-lived		$ 12,837
Weighted Average Life (in years)		12 years
Dacheng | Technology
Business Acquisition [Line Items]
Preliminary Fair Value, Definite-lived		$ 4,749
Weighted Average Life (in years)		12 years

Acquisitions - Summary of Unaud

Acquisitions - Summary of Unaudited Pro Forma Information (Detail) - Alfmeier $ in Thousands	3 Months Ended
	Mar. 31, 2022 USD ($)
Business Acquisition [Line Items]
Product revenues	$ 333,756
Net income	$ 8,567

Restructuring and Impairments -

Restructuring and Impairments - Additional Information (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	$ 1,269,000	$ 181,000
Description and timing of disposal	The Company is no longer pursuing a sale of the business and intends to wind-down the operations of the business by the end of 2023, subject to discussions with customers and suppliers.
Property and Equipment
Restructuring Cost And Reserve [Line Items]
Non-cash impairment charges			$ 690,000
Intangible Assets
Restructuring Cost And Reserve [Line Items]
Non-cash impairment charges			5,601,000
Inventory
Restructuring Cost And Reserve [Line Items]
Non-cash impairment charges	$ 1,419,000		$ 9,378,000
Manufacturing Footprint Rationalization
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	10,359,000
Other restructuring costs		101,000
Restructuring expenses remains accrued	588,000
Other Restructuring Activities
Restructuring Cost And Reserve [Line Items]
Other restructuring costs	63,000	30,000
Employee Separation Costs | Manufacturing Footprint Rationalization
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	0	$ 50,000
Employee Separation Costs | Other Restructuring Activities
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	$ 1,206,000

Restructuring and Impairments_2

Restructuring and Impairments - Summary of Restructuring Expense by Reportable Segment (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	$ 1,269	$ 181
Operating Segments | Automotive Segments
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	1,074	$ 181
Operating Segments | Corporate Segments
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	$ 195

Restructuring and Impairments_3

Restructuring and Impairments - Summary of Restructuring Liability (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Restructuring Cost And Reserve [Line Items]
Balance, beginning of period	$ 588
Additions, charged to restructuring expenses	1,269
Cash payments	(63)
Currency translation	16
Balance, end of period	1,810
Employee Separation Costs
Restructuring Cost And Reserve [Line Items]
Balance, beginning of period	588
Additions, charged to restructuring expenses	1,206
Currency translation	16
Balance, end of period	1,810
Other Related Costs
Restructuring Cost And Reserve [Line Items]
Additions, charged to restructuring expenses	63
Cash payments	$ (63)

Details of Certain Balance Sh_3

Details of Certain Balance Sheet Components (Detail) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022	Dec. 31, 2021
Current Assets:
Billable tooling	$ 16,296	$ 15,267
Income tax and other tax receivable	14,048	15,041
Notes receivable	13,075	12,127
Prepaid expenses	8,800	6,239
Short-term derivative financial instruments	8,548	6,564
Receivables due from factor	5,987	5,490
Other	2,937	3,869
Total other current assets	69,691	64,597
Other current liabilities:
Accrued employee liabilities	29,119	32,031
Liabilities from discounts and rebates	26,148	26,640
Income tax and other taxes payable	16,413	14,459
Accrued warranty	2,821	2,380	$ 1,772	$ 1,916
Restructuring	1,810	588
Other	12,585	17,716
Total other current liabilities	$ 88,896	$ 93,814

Goodwill and Other Intangible_2

Goodwill and Other Intangibles - Summary of Changes in the Carrying Amount of Goodwill, By Reportable Segment (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Goodwill [Line Items]
Balance, beginning of period	$ 119,774
Balance, end of period	120,955
Operating Segments
Goodwill [Line Items]
Balance, beginning of period	119,774
Currency translation	1,181
Balance, end of period	120,955
Automotive Segments | Operating Segments
Goodwill [Line Items]
Balance, beginning of period	73,069
Currency translation	949
Balance, end of period	74,018
Medical Segments | Operating Segments
Goodwill [Line Items]
Balance, beginning of period	46,705
Currency translation	232
Balance, end of period	$ 46,937

Goodwill and Other Intangible_3

Goodwill and Other Intangibles - Summary of Other Intangible Assets and Accumulated Amortization Balances (Detail) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Intangible Assets [Line Items]
Gross Carrying Value	$ 186,426	$ 183,846
Accumulated Amortization	(114,375)	(109,913)
Net Carrying Value	72,051	73,933
Net Carrying Value	72,051	73,933
Customer Relationships
Intangible Assets [Line Items]
Gross Carrying Value	113,909	112,286
Accumulated Amortization	(68,795)	(65,748)
Net Carrying Value	45,114	46,538
Technology
Intangible Assets [Line Items]
Gross Carrying Value	45,340	44,745
Accumulated Amortization	(26,696)	(25,709)
Net Carrying Value	18,644	19,036
Product development costs
Intangible Assets [Line Items]
Gross Carrying Value	19,051	18,774
Accumulated Amortization	(18,884)	(18,456)
Net Carrying Value	167	318
Software Development
Intangible Assets [Line Items]
Gross Carrying Value	1,007	1,007
Net Carrying Value	1,007	1,007
Tradenames
Intangible Assets [Line Items]
Gross Carrying Value	7,119	7,034
Net Carrying Value	$ 7,119	$ 7,034

Summary of Company's Debt (Deta

Summary of Company's Debt (Detail) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Total debt	$ 234,554	$ 235,096
Current maturities	(1,996)	(2,443)
Long-term debt, less current maturities	$ 232,558	$ 232,653
Revolving Credit Facility (U.S. Dollar denominations)
Debt Instrument [Line Items]
Interest Rate	6.28%	5.80%
Total debt	$ 232,000	$ 232,000
Other Loans
Debt Instrument [Line Items]
Total debt	$ 1,555	$ 2,011
Other Loans | Minimum
Debt Instrument [Line Items]
Interest Rate	3.90%	3.89%
Other Loans | Maximum
Debt Instrument [Line Items]
Interest Rate	5.21%	5.21%
Finance Leases
Debt Instrument [Line Items]
Total debt	$ 999	$ 1,085

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($)		3 Months Ended
	Jun. 10, 2022	Mar. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Maximum percentage of stock of non US subsidiaries pledge to secure obligation		66%
Second Amended and Restated Credit Agreement
Debt Instrument [Line Items]
Debt issuance cost	$ 1,417,000
Remaining borrowing capacity		$ 266,444,000
Second Amended and Restated Credit Agreement | Federal Funds Rate
Debt Instrument [Line Items]
Interest rate		0.50%
Second Amended and Restated Credit Agreement | SOFR Rate
Debt Instrument [Line Items]
Interest rate		1%
Base Rate Loans | Second Amended and Restated Credit Agreement | Minimum
Debt Instrument [Line Items]
Interest rate		0.125%
Base Rate Loans | Second Amended and Restated Credit Agreement | Maximum
Debt Instrument [Line Items]
Interest rate		1.125%
Term SOFR Rate Loans | Second Amended and Restated Credit Agreement | Minimum
Debt Instrument [Line Items]
Interest rate		1.125%
Term SOFR Rate Loans | Second Amended and Restated Credit Agreement | Maximum
Debt Instrument [Line Items]
Interest rate		2.125%
Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity increase subject to specified conditions	200,000,000
Revolving Credit Facility | Letters of Credit
Debt Instrument [Line Items]
Line of credit, outstanding amount		$ 0	$ 0
Revolving Credit Facility | Swing Line Loans
Debt Instrument [Line Items]
Maximum borrowing capacity	50,000,000
Revolving Credit Facility | Second Amended and Restated Credit Agreement
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 500,000,000
Debt maturity date	Jun. 10, 2027
Revolving Credit Facility | Second Amended and Restated Credit Agreement | Minimum
Debt Instrument [Line Items]
Commitment fee percentage payable on average daily unused amounts		0.175%
Revolving Credit Facility | Second Amended and Restated Credit Agreement | Maximum
Debt Instrument [Line Items]
Commitment fee percentage payable on average daily unused amounts		0.30%
Standby Letters of Credit | Second Amended and Restated Credit Agreement
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 15,000,000

Principal Maturities of Debt (D

Principal Maturities of Debt (Detail) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Debt maturing in 2023	$ 1,892
Debt maturing in 2024	440
Debt maturing in 2025	152
Debt maturing in 2026	70
Debt maturing in 2027	232,000
Total debt	234,554	$ 235,096
US and Euro Denominated Revolving Note
Debt Instrument [Line Items]
Debt maturing in 2027	232,000
Total debt	232,000
Other Debt
Debt Instrument [Line Items]
Debt maturing in 2023	1,892
Debt maturing in 2024	440
Debt maturing in 2025	152
Debt maturing in 2026	70
Total debt	$ 2,554

Commitments and Contingencies -

Commitments and Contingencies - Reconciliation of Changes in Accrued Warranty Costs (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Loss Contingency [Abstract]
Balance at the beginning of the period	$ 2,380	$ 1,916
Warranty claims paid	(559)	(334)
Warranty expense for products shipped during the current period	988	354
Adjustments to warranty estimates from prior periods	(6)	(152)
Adjustments due to currency translation	18	(12)
Balance at the end of the period	$ 2,821	$ 1,772

Commitments and Contingencies_2

Commitments and Contingencies - Additional Information (Detail) - Semiconductor Chips $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Loss Contingencies [Line Items]
Commitments	$ 40,593
Minimum
Loss Contingencies [Line Items]
Commitment period	12 months
Maximum
Loss Contingencies [Line Items]
Commitment period	24 months

Earnings Per Share (Detail)

Earnings Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Earnings Per Share [Abstract]
Net income	$ 7,963	$ 11,747
Basic weighted average shares of Common Stock outstanding	33,181,828	33,034,872
Dilutive effect of stock options, restricted stock awards and restricted stock units	204,306	341,892
Diluted weighted average shares of Common Stock outstanding	33,386,134	33,376,764
Basic earnings per share	$ 0.24	$ 0.36
Diluted earnings per share	$ 0.24	$ 0.35

Earnings Per Share - Additional

Earnings Per Share - Additional Information (Detail) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Earnings Per Share [Abstract]
Shares excluded from the Company’s diluted earnings	0	0

Financial Instruments - Additio

Financial Instruments - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Interest Rate Swap
Derivative [Line Items]
Hedge Ineffectiveness Incurred	$ 0	$ 0
Floating to Fixed interest Rate Swap
Derivative [Line Items]
Notional Value	$ 100,000,000
Maturity date	Jul. 31, 2025

Information Related to Recurrin

Information Related to Recurring Fair Value Measurement of Derivative Instruments in Our Consolidated Condensed Balance Sheet (Detail) - Fair Value, Inputs, Level 2 - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Foreign Currency Derivatives | Derivatives Designated as Cash Flow Hedges
Derivatives Fair Value [Line Items]
Notional Amount	$ 69,108	$ 40,063
Net Asset/ (Liabilities)	6,474	3,791
Foreign Currency Derivatives | Other Current Assets | Derivatives Designated as Cash Flow Hedges
Derivatives Fair Value [Line Items]
Asset Derivatives, Fair Value	6,474	3,791
Interest Rate Contracts | Derivatives Not Designated as Hedging Instruments
Derivatives Fair Value [Line Items]
Notional Amount	100,000	100,000
Net Asset/ (Liabilities)	2,073	2,772
Interest Rate Contracts | Other Current Assets | Derivatives Not Designated as Hedging Instruments
Derivatives Fair Value [Line Items]
Asset Derivatives, Fair Value	$ 2,073	$ 2,772

Information Related to Effect o

Information Related to Effect of Derivative Instruments on Our Consolidated Condensed Statements of Income and Consolidated Condensed Statements of Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Foreign Currency Derivatives
Derivative Instruments Gain Loss [Line Items]
Total foreign currency derivatives	$ 3,742	$ 763
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Comprehensive Income (Loss), Net of Tax	Other Comprehensive Income (Loss), Net of Tax
Commodity Hedges
Derivative Instruments Gain Loss [Line Items]
Total commodity derivatives		$ 13
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Comprehensive Income (Loss), Net of Tax	Other Comprehensive Income (Loss), Net of Tax
Interest Rate Contracts | Derivatives Not Designated as Hedging Instruments
Derivative Instruments Gain Loss [Line Items]
Total interest rate derivatives	$ (699)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Interest Income (Expense), Net	Interest Income (Expense), Net
Other comprehensive (loss) income | Foreign Currency Derivatives
Derivative Instruments Gain Loss [Line Items]
Total foreign currency derivatives	$ 2,683	$ 610
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Comprehensive Income (Loss), Net of Tax	Other Comprehensive Income (Loss), Net of Tax
Other comprehensive (loss) income | Commodity Hedges
Derivative Instruments Gain Loss [Line Items]
Total commodity derivatives		$ (6)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Comprehensive Income (Loss), Net of Tax	Other Comprehensive Income (Loss), Net of Tax
Cost of sales – income | Foreign Currency Derivatives
Derivative Instruments Gain Loss [Line Items]
Total foreign currency derivatives	$ 1,059	$ 153
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of Goods and Services Sold	Cost of Goods and Services Sold
Cost of sales – income | Commodity Hedges
Derivative Instruments Gain Loss [Line Items]
Total commodity derivatives		$ 19
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of Goods and Services Sold	Cost of Goods and Services Sold
Interest income, net | Interest Rate Contracts | Derivatives Not Designated as Hedging Instruments
Derivative Instruments Gain Loss [Line Items]
Total interest rate derivatives	$ (699)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Interest Income (Expense), Net	Interest Income (Expense), Net

Financial Instruments - Summary

Financial Instruments - Summary of Receivables Factored and Availability Under Receivables Factoring Agreements (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Receivables factored and outstanding	$ 21,034	$ 19,108
Amount available under the credit limit	3,321	5,034
Collective factoring limit	$ 24,355	$ 24,142

Financial Instruments - Summa_2

Financial Instruments - Summary of Trade Receivables Sold and Factoring Fees Incurred (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Trade receivables sold	$ 38,540
Factoring fees incurred	$ 161

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Fair Value, Recurring Basis
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Financial assets, fair value	$ 0	$ 0
Financial liabilities, fair value	0	0
Fair Value, Nonrecurring Basis
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Financial assets, fair value	0	0
Financial liabilities, fair value	$ 0	$ 0

Equity - Additional Information

Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2020
Class Of Stock [Line Items]
Shares repurchased	9,997
Average cost per share	$ 59.27
Remaining authorized repurchase amount	$ 120,003
2020 Stock Repurchase Program
Class Of Stock [Line Items]
Stock repurchase program period		3 years
Stock repurchase program expiration date		Dec. 15, 2023
Maximum | 2020 Stock Repurchase Program
Class Of Stock [Line Items]
Stock repurchase program, authorized to repurchase amount		150,000

Schedule of Reclassification Ad

Schedule of Reclassification Adjustments and Other Activities Impacting Accumulated Other Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2023		Mar. 31, 2022
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance		$ (46,489)		$ (36,922)
Other comprehensive (loss) income before reclassifications		11,933		(8,378)
Income tax effect of other comprehensive income (loss) before reclassifications		(751)		(322)
Amounts reclassified from accumulated other comprehensive income (loss) into net income		(1,053)		(137)
Income taxes reclassified into net income		259		31
Other comprehensive income (loss), net of tax		10,388		(8,806)
Ending Balance		(36,101)		(45,728)
Defined Benefit Pension Plans
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance		(1,067)		(2,893)
Amounts reclassified from accumulated other comprehensive income (loss) into net income		6		35
Income taxes reclassified into net income		(2)		(6)
Other comprehensive income (loss), net of tax		4		29
Ending Balance		(1,063)		(2,864)
Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance		(48,269)		(34,188)
Other comprehensive (loss) income before reclassifications		8,191		(9,154)
Income tax effect of other comprehensive income (loss) before reclassifications		64		(140)
Other comprehensive income (loss), net of tax		8,255		(9,294)
Ending Balance		(40,014)		(43,482)
Foreign Currency Hedge Derivatives
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance		2,847		154
Other comprehensive (loss) income before reclassifications		3,742		763
Income tax effect of other comprehensive income (loss) before reclassifications		(815)		(179)
Amounts reclassified from accumulated other comprehensive income (loss) into net income		(1,059)	[1]	(153)	[2]
Income taxes reclassified into net income		261		33
Other comprehensive income (loss), net of tax		2,129		464
Ending Balance		$ 4,976		618
Commodity Hedge Derivatives
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance				5
Other comprehensive (loss) income before reclassifications				13
Income tax effect of other comprehensive income (loss) before reclassifications				(3)
Amounts reclassified from accumulated other comprehensive income (loss) into net income	[2]			(19)
Income taxes reclassified into net income				4
Other comprehensive income (loss), net of tax				$ (5)
[1] The amounts reclassified from accumulated other comprehensive loss were included in cost of sales. The amounts reclassified from accumulated other comprehensive loss were included in cost of sales.

Income Taxes - Summary of Provi

Income Taxes - Summary of Provision for Income Taxes and Corresponding Effective Tax Rate (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income tax expense	$ 3,728	$ 4,295
Earnings before income tax	$ 11,691	$ 16,042
Effective tax rate	31.90%	26.80%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income tax expense	$ 3,728	$ 4,295
Earnings before income tax	$ 11,691	$ 16,042
Effective tax rate	31.90%	26.80%
Effect of the settlement and closure of a multi-year state audit	$ 454
Adjusted for the audit impacts, effective rate	28%
U.S. federal statutory rate	21%	21%

Segment Reporting - Segment Inf

Segment Reporting - Segment Information about Reported Product Revenues, Depreciation and Amortization and Operating Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Segment Reporting Information [Line Items]
Product revenues	$ 363,625	$ 267,657
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember
Depreciation and amortization	$ 13,583	$ 9,577
Operating income (loss)	17,674	14,190
Automotive Segments
Segment Reporting Information [Line Items]
Product revenues	$ 352,692	$ 257,864
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember
Depreciation and amortization	$ 12,290	$ 8,667
Operating income (loss)	38,379	31,275
Medical Segments
Segment Reporting Information [Line Items]
Product revenues	$ 10,933	$ 9,793
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember
Depreciation and amortization	$ 978	$ 604
Operating income (loss)	$ (493)	$ (851)
Corporate Segments
Segment Reporting Information [Line Items]
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember
Depreciation and amortization	$ 265	$ 306
Operating income (loss)	$ (20,212)	$ (16,234)

Segment Reporting - Segment I_2

Segment Reporting - Segment Information About Reported Segment Product Revenues by Product Category (Detail) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2023	Mar. 31, 2022
Segment Reporting Information [Line Items]
Product revenues		$ 363,625	$ 267,657
Automotive Segments
Segment Reporting Information [Line Items]
Product revenues		352,692	257,864
Automotive Segments | Climate Control Seat
Segment Reporting Information [Line Items]
Product revenues		114,753	102,734
Automotive Segments | Seat Heaters
Segment Reporting Information [Line Items]
Product revenues		75,636	68,896
Automotive Segments | Lumbar and Massage Comfort Solutions
Segment Reporting Information [Line Items]
Product revenues	[1]	38,738
Automotive Segments | Steering Wheel Heaters
Segment Reporting Information [Line Items]
Product revenues		36,347	28,736
Automotive Segments | Automotive Cables
Segment Reporting Information [Line Items]
Product revenues		20,220	22,045
Automotive Segments | Battery Performance Solutions
Segment Reporting Information [Line Items]
Product revenues		20,309	17,613
Automotive Segments | Electronics
Segment Reporting Information [Line Items]
Product revenues		10,970	10,828
Automotive Segments | Valve System
Segment Reporting Information [Line Items]
Product revenues	[1]	26,994
Automotive Segments | Other Automotive
Segment Reporting Information [Line Items]
Product revenues		8,725	7,012
Industrial Segments | Medical Segments
Segment Reporting Information [Line Items]
Product revenues	[2]	$ 10,933	$ 9,793
[1] Represents product revenues from Alfmeier (acquired on August 1, 2022) - (see Note 2) Includes product revenues of $ 1,279 from Dacheng (acquired on July 13, 2022) - (see Note 2)

Segment Reporting - Segment I_3

Segment Reporting - Segment Information About Reported Segment Product Revenues by Product Category (Parenthetical) (Details) - USD ($) $ in Thousands		3 Months Ended
	Jul. 13, 2022	Mar. 31, 2023	Mar. 31, 2022
Segment Reporting Information [Line Items]
Product revenues		$ 363,625	$ 267,657
Automotive Segments
Segment Reporting Information [Line Items]
Product revenues		352,692	257,864
Medical Segments
Segment Reporting Information [Line Items]
Product revenues		$ 10,933	$ 9,793
Medical Segments | Dacheng
Segment Reporting Information [Line Items]
Product revenues	$ 1,279

Segment Reporting - Product Rev

Segment Reporting - Product Revenues Information by Geographic Area (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Segment Reporting Information [Line Items]
Product revenues	$ 363,625	$ 267,657
Revenue, Product and Service [Extensible Enumeration]	us-gaap:ProductMember	us-gaap:ProductMember
United States
Segment Reporting Information [Line Items]
Product revenues	$ 141,452	$ 104,122
China
Segment Reporting Information [Line Items]
Product revenues	46,654	38,353
South Korea
Segment Reporting Information [Line Items]
Product revenues	28,738	21,175
Germany
Segment Reporting Information [Line Items]
Product revenues	26,512	19,786
Czech Republic
Segment Reporting Information [Line Items]
Product revenues	17,650	10,808
Japan
Segment Reporting Information [Line Items]
Product revenues	15,222	11,816
Romania
Segment Reporting Information [Line Items]
Product revenues	12,533	12,755
Slovakia
Segment Reporting Information [Line Items]
Product revenues	11,596	8,536
Finland
Segment Reporting Information [Line Items]
Product revenues	10,133	7,893
Mexico
Segment Reporting Information [Line Items]
Product revenues	9,094	4,547
Other
Segment Reporting Information [Line Items]
Product revenues	44,041	27,866
Non U.S.
Segment Reporting Information [Line Items]
Product revenues	$ 222,173	$ 163,535